Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predicting Recurrence of Abnormal Vaginal Flora After Metronidazole
NCT01287728Phase 3Completed
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Jan 2011
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of metronidazole in bacterial vaginosis (BV), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Value of A. vaginae and G. vaginalis loads in predicting recurrence of abnormal vaginal flora at 12 months. Started Jan 2011; status: completed.
02
Drugs
metronidazole
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT01287728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01287728.